Drugs / Minhai-HIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02560272 | Sep 2014 → Dec 2015 | haemophilus infectious disease | Beijing Minhai Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minhai-HIB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02560272 ↗ |
| Modality | Vaccine | “Haemophilus Influenzae Type b Conjugate Vaccine” NCT02560272 ↗ |
| Route | Intramuscular | “0.5ml, intramuscular” NCT02560272 ↗ |